- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06003972
Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure (Copaxone)
Assess the anti-inflammatory effects of short-term Copaxone therapy on patients with acute decompensated heart failure.
Trial Design
- An open-label, randomized, prospective trial of patients hospitalized due to acute decompensation of heart failure with reduced ejection fraction.
- Patients will be enrolled within 24 hours from hospital admission.
- Randomization and intervention will begin within 24 hours of enrollment (and at least 24 hours after admission).
- Patients will be randomized in a 1:1 ratio either to receive guideline directed medical therapy (GDMT) or GDMT plus Copaxone.
- Patients assigned to intervention group will receive daily SC Copaxone 20 mg for 14 days.
- Patients will be assessed during 4 time points(screening/randomization, visit 3 day, visit 14 day, visit 30 day) as elaborated in article "monitoring".
- Changes in inflammatory cytokines will be compared between control and intervention group throughout 3 time points.
- The trial will be approved by the institutional view board and conducted in accordance with the principles or Good Clinical Practice guidelines and the Declaration of Helsinki.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Jerusalem, Israel, 911002
- Hadassah Ein Kerem medical center-hospital ,Cardiology Department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- STAGE CHF BASELINE NYHA functional class II-III and established diagnosis of ischemic cardiomyopathy
- Hospitalization due to acute decompensated CHF
- GDMT for at least 3 months prior to enrollment
Exclusion Criteria:
- Current hospitalization:
- Hemodynamic instability necessitating inotropic or mechanical circulatory support
- Respiratory failure necessitating invasive mechanical ventilation
- Active infection
- A different etiology to explain SIRS other than CHF exacerbation.
Prior hospitalizations or need of intravenous diuretic therapy in the last 30 days before current hospitalization
Cardiac co-morbidities:
Specific HF etiologies:
- Pericardial disease
- Infiltrative myocardial disease
- Moderate and above Valvular heart disease Acute coronary syndrome in the preceding 60 days to randomization Evidence of significant cardiac ischemia within 1 year of randomization without revascularization since Stroke or TIA in the preceding 30 days from randomization
Complex congenital cardiac defect
New initiation of cardiac resynchronization therapy within 60 days prior to randomization
Life threatening arrhythmias /ICD ACTIVATION- in last 90 days Listing for heart transplantation or anticipated/implanted ventricular assist device
Non-cardiac co-morbidities:
- Glomerular filtration rate <30 mL/min/1.73m2 calculated by MDRD formula
- Hepatic insufficiency classified as Child-Pugh B or C
- SBP >180 mm Hg or <110 mm Hg NOT RESPONSIVE TO THERAPY
- Morbid obesity with a BMI >40 kg/m2
- Severe pulmonary disease with requirement of home oxygen therapy or important nocturnal desaturation
- Active treatment for malignancy in the past 2 years or neoplastic spread beyond organ of origin (lymphatic metastases included)
- Hemoglobin <8 g/dL
- Known previous systemic inflammatory disease
- Alcohol or drug abuse Chronic treatment with Copaxone, cytotoxic, immunosuppressant or biological treatment in the past two years.
Known Pregnancy Incapability of signing IC due to cognitive or mental reason Poor compliance to medical therapy or inability to complete the study Age >80 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
This arm serves as the control arm, patients allocated receive guideline directed medical therapy only
|
GDMT for heart failure according to the AHA guidelines.
|
Experimental: Copaxone arm
Patients receive guideline directed medical therapy with an add-on GA therapy for 14 days
|
Paptients allocated to this arm receive 20 mg GA given s.c daily for a total of 14 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Endpoint
Time Frame: 3 weeks
|
%change in inflammatory cytokines from baseline to Day 3 and 2 weeks (up to 3 weeks), compared between intervention vs. control groups
|
3 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Offer Amir, PhD, Hadassah Medical Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Systemic Inflammatory Response Syndrome
- Inflammation
- Shock
- Heart Failure
- Cytokine Release Syndrome
- Physiological Effects of Drugs
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Adjuvants, Immunologic
- Glatiramer Acetate
- (T,G)-A-L
Other Study ID Numbers
- 093418-HMO-CTIL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on guideline directed medical therapy (GDMT)
-
The First Affiliated Hospital with Nanjing Medical...West China Hospital; Fujian Medical University Union Hospital; Chinese Academy... and other collaboratorsRecruitingHeart Failure | Left Bundle-Branch Block | Non-ischemic CardiomyopathyChina
-
Pulnovo Medical (Wuxi) Co., Ltd.The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsRecruitingCardiovascular Diseases | Vascular Diseases | Heart Failure | Hypertension | Pulmonary Hypertension | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection FractionChina
-
Chongqing Medical UniversityCompletedHeart Failure With Reduced Ejection FractionChina
-
Medtronic CardiovascularRecruitingAortic Stenosis Symptomatic | Moderate Aortic Valve StenosisUnited States, France, Netherlands, Canada, Spain, Israel, Australia, Denmark, Germany, Italy, Japan, Switzerland, Belgium, Sweden, Austria, United Kingdom, Ireland
-
Ancora Heart, Inc.RecruitingDilated Cardiomyopathy | Heart Failure With Reduced Ejection Fraction (HFrEF)United States, France, Netherlands, Czechia, Belarus, Belgium, Serbia
-
Montreal Heart InstituteAbbott Medical DevicesUnknownHeart Failure | Mitral Regurgitation | Mitral Valve Regurgitation Due to Cardiomyopathy (Disorder)Canada
-
Sun Yat-sen UniversityRecruitingFunctional Mitral RegurgitationChina
-
Edwards LifesciencesTerminatedMitral Regurgitation | Mitral Insufficiency | Functional Mitral RegurgitationUnited States
-
Harbin Medical UniversityShanghai Shenqi Medical Technology Co., LtdNot yet recruitingAcute Coronary Syndrome (ACS)China
-
Duke UniversityThe University of Texas Health Science Center, Houston; National Heart, Lung... and other collaboratorsRecruitingType B Aortic DissectionUnited States